Skip to main content
CMEducation Resources ScrollCall
  • menu
  • menu
  • person
  • Search
Interventional Cardiology
Medical & Preventive Cardiology
Lipidology & Atherosclerosis Prevention
CV RISK/DIABETES
A MULTI-SPECIALTY PERSPECTIVE
  • close
CMEducation Resources iQ&A
  • person
  • Home
  • Specialtieschevron_right
    • chevron_leftTopics
    • PCSK9s in Interventional Cardiology
    • PCSK9s in Medical and Preventive Cardiology
    • Lipidology & Atherosclerosis Prevention
    • CV Risk/Diabetes
    • A Multi-Specialty Perspective
  • Submit A Question
close

Ulf Landmesser MD, FESC

Ulf Landmesser MD, FESC

Professor of Cardiology

Medical Director, Department of Cardiology

Charite University Hospital

Berlin, Germany


Related Videos

Based on ODYSSEY Outcomes, which patients in an interventional cardiology practice do you believe will benefit most from PCSK9 inhibition? Video

Based on ODYSSEY Outcomes, which patients in an interventional cardiology practice do you believe will benefit most from PCSK9 inhibition?

In your interventional cardiology practice, which markers of risk, in the patient who has undergone a PCI, do you focus on to promote consideration for using a PCSK9 inhibitor? Video

In your interventional cardiology practice, which markers of risk, in the patient who has undergone a PCI, do you focus on to promote consideration for using a PCSK9 inhibitor?

With respect to patients with HeFH and homozygous FH who are challenged with lifelong CV disease risk burden due to genetic risk, what role do you believe PCSK9 inhibitors should play, especially in younger patient populations? Video

With respect to patients with HeFH and homozygous FH who are challenged with lifelong CV disease risk burden due to genetic risk, what role do you believe PCSK9 inhibitors should play, especially in younger patient populations?

Within the context of the ESC and U.S. guidelines for LDL-C reduction, which recommend 70 mg/dL as a threshold target, how should we view the cholesterol landscape between 20 mg/dL and 70 mg/dL in light of the ODYSSEY Outcomes Trial? Video

Within the context of the ESC and U.S. guidelines for LDL-C reduction, which recommend 70 mg/dL as a threshold target, how should we view the cholesterol landscape between 20 mg/dL and 70 mg/dL in light of the ODYSSEY Outcomes Trial?

Can you discuss the ESC Guidelines for LDL-C targets and the recent AHA Guidelines designating a target threshold of 70 mg/DL? Is this low enough? What is your recommendation for PCSK9 inhibition in the high-risk ACS patient who has undergone PCI? Video

Can you discuss the ESC Guidelines for LDL-C targets and the recent AHA Guidelines designating a target threshold of 70 mg/DL? Is this low enough? What is your recommendation for PCSK9 inhibition in the high-risk ACS patient who has undergone PCI?

What has been your clinical experience with respect to the comparative toleration of statins vs. PCSK9 inhibitors? Video

What has been your clinical experience with respect to the comparative toleration of statins vs. PCSK9 inhibitors?

Disclaimer:
Copyright © by CMEducation Resources, LLC All rights reserved. Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.
Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Clinical Webcasts®

Powered by BroadcastMedBROADCASTMED